These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31582422)

  • 1. A Novel Small Molecule Inhibits Tumor Growth and Synergizes Effects of Enzalutamide on Prostate Cancer.
    Cheng J; Moore S; Gomez-Galeno J; Lee DH; Okolotowicz KJ; Cashman JR
    J Pharmacol Exp Ther; 2019 Dec; 371(3):703-712. PubMed ID: 31582422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Chen X; Liu J; Cheng L; Li C; Zhang Z; Bai Y; Wang R; Han T; Huang C; Kong Y; Feng F; Liu X
    Prostate; 2020 Feb; 80(3):256-266. PubMed ID: 31856338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
    Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
    Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
    Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
    FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic cancer drug-sensitivity predicted by synergy of p53-Activator Wnt Inhibitor-2 (PAWI-2) and protein biomarker expression.
    Cheng J; Cashman JR
    Invest New Drugs; 2021 Feb; 39(1):131-141. PubMed ID: 32915418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
    Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of PAWI-2 on pancreatic cancer stem cell tumors.
    Cashman JR; Cashman EA
    Invest New Drugs; 2024 Aug; 42(4):353-360. PubMed ID: 38789849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.
    Wu H; Zhang L; Gao X; Zhang X; Duan J; You L; Cheng Y; Bian J; Zhu Q; Yang Y
    Cancer Lett; 2017 Jan; 385():108-116. PubMed ID: 27815035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.
    Liu C; Lou W; Zhu Y; Yang JC; Nadiminty N; Gaikwad NW; Evans CP; Gao AC
    Cancer Res; 2015 Apr; 75(7):1413-22. PubMed ID: 25649766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mifepristone Has Limited Activity to Enhance the
    Yang Y; Li X; Mamouni K; Kucuk O; Wu D
    Anticancer Res; 2017 Nov; 37(11):6235-6243. PubMed ID: 29061806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.
    Guerrero J; Alfaro IE; Gómez F; Protter AA; Bernales S
    Prostate; 2013 Sep; 73(12):1291-305. PubMed ID: 23765603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells.
    Ghashghaei M; Niazi TM; Heravi M; Bekerat H; Trifiro M; Paliouras M; Muanza T
    Prostate; 2018 Jan; 78(1):64-75. PubMed ID: 29134684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models.
    Weyer-Czernilofsky U; Hofmann MH; Friedbichler K; Baumgartinger R; Adam PJ; Solca F; Kraut N; Nguyen HM; Corey E; Liu G; Sprenger CC; Plymate SR; Bogenrieder T
    Mol Cancer Ther; 2020 Apr; 19(4):1059-1069. PubMed ID: 32054790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X
    J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PMA induces androgen receptor downregulation and cellular apoptosis in prostate cancer cells.
    Itsumi M; Shiota M; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    J Mol Endocrinol; 2014 Aug; 53(1):31-41. PubMed ID: 24780839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzalutamide inhibits testosterone-induced growth of human prostate cancer xenografts in zebrafish and can induce bradycardia.
    Melong N; Steele S; MacDonald M; Holly A; Collins CC; Zoubeidi A; Berman JN; Dellaire G
    Sci Rep; 2017 Oct; 7(1):14698. PubMed ID: 29089623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting prostate cancer cells with enzalutamide-HDAC inhibitor hybrid drug 2-75.
    Hu WY; Xu L; Chen B; Ou S; Muzzarelli KM; Hu DP; Li Y; Yang Z; Vander Griend DJ; Prins GS; Qin Z
    Prostate; 2019 Jul; 79(10):1166-1179. PubMed ID: 31135075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
    Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
    Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells.
    Verma K; Gupta N; Zang T; Wangtrakluldee P; Srivastava SK; Penning TM; Trippier PC
    Mol Cancer Ther; 2018 Sep; 17(9):1833-1845. PubMed ID: 29891491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer.
    Yamamoto Y; Lin PJ; Beraldi E; Zhang F; Kawai Y; Leong J; Katsumi H; Fazli L; Fraser R; Cullis PR; Gleave M
    Clin Cancer Res; 2015 Nov; 21(21):4845-55. PubMed ID: 26106075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.